> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Clovis NDA for Lung Cancer
- URL: https://www.fdaweb.com/panel-to-discuss-clovis-nda-for-lung-cancer/
- Published: 2016-02-16T12:00:00.000Z
- Updated: 2026-09-15T02:36:14.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5134786

*Federal Register* Notice: FDA’s Oncologic Drugs Advisory Committee will meet 4/12 from 8:30 a.m. to 1 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss a Clovis Oncology NDA for rociletinib tablets for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation as detected by an FDA approved test. Contact **Lauren D. Tesh**, (301) 796-9001\. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-02-16/pdf/2016-03011.pdf?ref=fdaweb.com)